Studies related to Infantile Colic and Lactobacillus reuteri

Lactobacillus Reuteri DSM 17938 For The Management Of Infantile Colic In Breastfed Infants: A Randomized, Double-blind, Placebo-controlled Trial

Effect Decrease
Trial Design Double blind
Trial Length 2-4 Weeks
Number of Subjects 80
Gender Both Genders
Age Range 0-1
Notes for this study:
A once daily dose of 10^8^ CFU _l. reuteri_ DSM 17938 to colic infants for four weeks times significantly reduced crying within one week (six infants reporting more than a halving in crying with none in placebo) and after one month all infants reporting more than a halving of crying (60% in placebo).

Prophylactic Use Of A Probiotic In The Prevention Of Colic, Regurgitation, And Functional Constipation: A Randomized Clinical Trial

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 468
Gender Both Genders
Age Range 0-1
Body Types Average
Notes for this study:
Administration of _l. reuteri_ DSM 17938 to infants during the first three months of life greatly reduced the occurrence of infantile colic relative to placebo, and also improve gastrointestinal symptoms such as increasing bowel evacuations (reducing risk of constipation) and regurgitations.

Ultimately, prophylactic treatment of infants with DSM 17938 resulted in less pediatric department visits and was estimated to save both parent and community over $200 (USD).

Lactobacillus Reuteri DSM 17938 In Infantile Colic: A Randomized, Double-blind, Placebo-controlled Trial

Effect Decrease
Trial Design Double blind
Trial Length 2-4 Weeks
Number of Subjects 46
Gender Both Genders
Age Range 0-1
Body Types Average
Notes for this study:
Supplementation of a dropper containing 10^8^ CFU of _l. reuteri_ DSM 17938 daily for three weeks in colic infants was able to reduce crying time overall more than placebo after three weeks with more babies having a 50% or greater reduction in crying time after every week.

Treating Infant Colic With The Probiotic Lactobacillus Reuteri: Double Blind, Placebo Controlled Randomised Trial

Effect Increase
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 127
Gender Both Genders
Age Range 0-1
Notes for this study:
Supplementation of _l. reuteri_ DSM 17938 at 10^8^ CFU daily in infants with colic failed to find any evidence of benefit with probiotic, instead finding a significant increase in crying with supplementation relative to placebo. Other secondary endpoints of colic (sleep duration per night, parental visits to pediatricians) did not differ between groups.

Lactobacillus Reuteri (American Type Culture Collection Strain 55730) Versus Simethicone In The Treatment Of Infantile Colic: A Prospective Randomized Study

Effect Decrease
Trial Design Cohort
Trial Length 2-4 Weeks
Number of Subjects 83
Gender Both Genders
Age Range 0-1
Notes for this study:
_L. reuteri_ ATCC 55730 given at 10^8^ CFU daily in infants with colic appeared to cause significant improvements in colic symptoms over the course of one month, with crying being reduced relative to baseline and the active control (simethicone) within one week and after a month the responders to reuteri (reporting more than a 50% reduction in crying) reached 95% as total crying was reduced 75%.

Probiotics To Prevent Or Treat Excessive Infant Crying: Systematic Review And Meta-analysis

Effect Decrease
Trial Design Meta analysis
Trial Length n/a
Number of Subjects 3
Gender n/a
Notes for this study:
While this meta-analysis confirmed that the studies investigating _L. reuteri_ (n=3) collectively found a significant beneficial effect of supplementation relative to placebo, all studied trials had potential biases included (usually due to the study itself being funded by the main producer of _L. reuteri_ DSM 17938 or authors being associated with the company; BioGaia).

454 Pyrosequencing Analysis On Faecal Samples From A Randomized DBPC Trial Of Colicky Infants Treated With Lactobacillus Reuteri DSM 17938

Effect Decrease
Trial Design Double blind
Trial Length 2-4 Weeks
Number of Subjects 29
Gender Both Genders
Age Range 0-1
Notes for this study:
In a study designed to see the efficacy of _l. reuteri_ DSM 17938 in reducing colic in infants as it relates to their gut microbiome, it was noted that supplementation (relative to placebo) had two thirds of its group report over a 50% reduction in crying relative to one infant (12.5%) in the placebo group.